on ABIVAX (EPA:ABVX)
Crossing of threshold at ABIVAX: statement from Sofinnova
On February 17, 2025, Sofinnova Partners informed ABIVAX of a crossing of the voting rights threshold. As of July 6, 2024, Sofinnova held 8.37% of the capital and 10.27% of the voting rights. The increase is due in particular to the allocation of double voting rights.
Currently, Sofinnova owns 8.31% of the capital and 10.98% of the voting rights of the company. The institute does not plan to purchase more shares or take control of ABIVAX. The aim is to continue supporting ABIVAX in its efforts to develop its products and seek financing.
Sofinnova specifies that it is not a party to agreements mentioned in Article L. 233-9 of the French Commercial Code, nor does it plan any significant structural changes within ABIVAX.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news